Biohaven/Pfizer Partnered Rimegepant Asia-Pacific Migraine Trial Meets Primary Endpoints

Biohaven Pharmaceutical Holding Company Ltd BHVN and Pfizer Inc PFE reported topline results from an Asia-Pacific, Phase 3 trial of rimegepant in adults for the acute treatment of migraine. 

• The study met its co-primary endpoints of freedom from pain and freedom from most bothersome migraine-associated symptom, including either nausea, phonophobia, or photophobia at 2-hours following a single oral dose of rimegepant.
• In the study, a single oral dose of rimegepant 75 mg provided significant relief of migraine symptoms and return to normal function at 2 hours and delivered sustained efficacy that lasted up to 48 hours for many patients. 
• Related: Biohaven's Zavegepant Pain Spray Aces Late-Stage Migraine Trial.
• Rimegepant showed a favorable safety and tolerability profile, the company said.
• Pfizer has commercialization rights to rimegepant in markets outside of the U.S. Biohaven continues to lead research and development globally and retains the U.S. market. 
• Rimegepant is commercialized as Nurtec ODT in the U.S. and is the only oral CGRP receptor antagonist approved for acute and preventive migraine treatment in adults. 
• Rimegepant application is currently under review by the European Medicines Agency, with a decision expected in 1H of 2022. 
• Price Action: PFE stock is down 1.26% at $50.14 during the premarket session on the last check Monday. BHVN closed at $134.84 on Friday.